[vc_row type=”full_width_background” full_screen_row_position=”middle” bg_image=”9144″ bg_position=”center center” bg_repeat=”no-repeat” scene_position=”center” text_color=”dark” text_align=”left” top_padding=”360″ overlay_strength=”0.3″ shape_divider_position=”bottom” bg_image_animation=”none” shape_type=””][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none”][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” scene_position=”center” text_color=”dark” text_align=”left” overlay_strength=”0.3″ shape_divider_position=”bottom” bg_image_animation=”none” full_width=”stretch_row_content_no_spaces” css=”.vc_custom_1556108564202{background-image: url(https://www.selectimmune.com/wp-content/uploads/2019/04/projects_1.jpg?id=371) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”min-h-70vh”][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none”][vc_column_text css=”.vc_custom_1684253390272{margin-top: 3em !important;margin-right: 0px !important;margin-left: 0px !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”]

Infections

[/vc_column_text][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” scene_position=”center” text_color=”dark” text_align=”left” overlay_strength=”0.3″ shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none”][vc_column_text inpublix_narrow_column=”1″]

Infections continue to threaten human health. Pathogenic bacteria rapidly develop resistance against antibiotics. Antibiotic resistance is a global, rapidly growing health concern. The World Health Organization (WHO) has declared antibiotic resistance a major threat to global health. Hamlet Biopharma develops novel therapies against infection with the goal to provide a immunotherapy as a molecular framework for the treatment of bacterial infections; much needed to combat antibiotic resistance. One of the main drug candidates, the Interleukin-1 receptor antagonist (IL1-RA), has successfully been used in the clinic to treat bladder pain syndrome and is currently being investigated in controlled Phase II trials.

[/vc_column_text][divider line_type=”No Line” custom_height=”40″][/vc_column][/vc_row][vc_row type=”in_container” full_screen_row_position=”middle” equal_height=”yes” scene_position=”center” text_color=”dark” text_align=”left” overlay_strength=”0.3″ shape_divider_position=”bottom” bg_image_animation=”none”][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/4″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none” css=”.vc_custom_1556092004313{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][image_with_animation image_url=”9268″ alignment=”center” animation=”Fade In” border_radius=”none” box_shadow=”none” max_width=”100%”][divider line_type=”No Line” custom_height=”10″][vc_column_text]

IL1-receptor antagonists

IL-1 receptor antagonist (Kineret) to treat acute infections and prevent tissue damage

[/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/4″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none” css=”.vc_custom_1556092339693{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][image_with_animation image_url=”9269″ alignment=”center” animation=”Fade In” border_radius=”none” box_shadow=”none” max_width=”100%”][divider line_type=”No Line” custom_height=”10″][vc_column_text]

NK1R-inhibitors

A nerve cell receptor antagonist prevents pain and tissue damage during acute infections

[/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/4″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none” css=”.vc_custom_1556092379385{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][image_with_animation image_url=”9270″ alignment=”center” animation=”Fade In” border_radius=”none” box_shadow=”none” max_width=”100%”][divider line_type=”No Line” custom_height=”10″][vc_column_text]

RNA Pol II inhibitors

A small molecule from ”nice bacteria” prevents over-activation of immunity and reduces inflammation

[/vc_column_text][/vc_column][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/4″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none” css=”.vc_custom_1556092403938{background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][image_with_animation image_url=”9271″ alignment=”center” animation=”Fade In” border_radius=”none” box_shadow=”none” max_width=”100%”][divider line_type=”No Line” custom_height=”10″][vc_column_text]

IRF7 inhibitors

New molecular tools to inhibit ‘’bad’’ inflammation in infected tissue and reduce the risk of sepsis

[/vc_column_text][/vc_column][/vc_row]